Trial Profile
Early Phase 2 Clinical Trial of E6011 in Patients With Active Crohn's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Quetmolimab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors EA Pharma
- 12 Dec 2023 Planned End Date changed from 30 Sep 2024 to 1 Apr 2024.
- 04 Oct 2022 Planned primary completion date changed from 30 Sep 2022 to 31 Oct 2022.
- 01 Aug 2022 Planned End Date changed from 30 Sep 2025 to 30 Sep 2024.